Dr. Mariola Söhngen,
Chief Executive Officer (CEO)

Dr Mariola Soehngen joined the Executive Board of MOLOGEN AG in November 2015 as Chief Executive Officer.

She has acquired a wealth of experience in the biotechnological and pharmaceutical industry. Dr Soehngen is co-founder of both PAION AG and PAION Deutschland GmbH and served as a Managing Director since the foundation. In addition, from 2004 to 2015 she held the position of Chief Medical Officer (CMO) of PAION AG. In this function she was responsible for clinical drug development Phase I-IV, Regulatory, Drug Safety, Quality Assurance and other areas.

Until the foundation of PAION she worked for globally operating pharmaceutical companies Grünenthal GmbH and Ferrer Internacional S.A. (its subsidiary Trommsdorf GmbH & Co. KG Arzneimittel ). There she was responsible for Project Coordination, Licencing, Strategic Project Evaluation and Interfacing with Marketing. In 1998 she founded her own company, Bootcamp, which prepared entrants in the job market for professions in the healthcare industry.

Following her medical degree in 1987, Dr Soehngen obtained both a PhD in Medicine (1988), a Diploma in Pharmaceutical Medicine (DGPharMed, 1996) and Master of Business Communication (1999).

Dr Soehngen was born in 1961and is a German citizen. She is married and has three children.

Areas of responsibility at MOLOGEN:

  • Business Development
  • Investor Relations & Corporate Communications
  • Partnering
  • Production
  • Strategy

External mandates:

  • Vita 34 AG [ISIN DE000A0BL849], Member of the Supervisory Board

Walter Miller,
Chief Financial Officer (CFO)

Walter Miller became the new Chief Financial Officer of MOLOGEN AG in April 2016.

He has more than 15 years of experience in the biotech and pharmaceutical industry, in both startups and listed companies. In 2013, he became the authorized signatory and commercial director (CFO) of Nuvisan GmbH, Germany, an international contract research organization (CRO) and laboratory service provider, where he assumed responsibility for the commercial and administrative areas of the company. Prior to this, between 2002 and 2013, he held various management positions in the Santhera Pharmaceuticals Group, initially in Germany and later in Switzerland, most recently as Vice President Finance & Commercial Operations and as a Member of the Executive Board. In particular, his remit included the development of the organization, the accounting system and project controlling as well as handling strategic financial matters and in- and out-licensing activities. Furthermore, he was significantly involved in the cross-border merger, the initial public offering (IPO) on the SIX Swiss Exchange and various financing deals.

Before entering the biotech and pharmaceutical industry, Walter Miller’s last position was as Head of Accounting and Controlling at Parsytec AG, Germany. In this role, his responsibility covered the Group’s international consolidated financial statements in accordance with US-GAPP, project controlling and the finances of foreign subsidiaries. In addition, he was on the IPO team in 1999.

Walter Miller obtained his qualification for Business Administration (FH) in Aachen, Germany,
in 1997. He was also awarded a Baccalaureate in the Science of Marriage and Family in 1994 (comparable with a Bachelor of Arts) and the Controller’s Diploma at the Controller Akademie Gauting, near Munich, in 2004.

He was born in 1967 and has the German citizenship. Walter Miller is married and has a son.

Areas of responsibility at MOLOGEN:

  • Compliance and Corporate Governance
  • Finance and Administration 
  • Human Resources
  • IT
  • Legal
  • Risk Management

External mandates:

  • Walter Miller currently does not hold any other board memberships.

Dr. Matthias Baumann,
Chief Medical Officer (CMO)

Dr Baumann joined Mologen in May 2017 as Chief Medical Officer and Member of the Executive Board.

He has more than 26 years of experience in the healthcare industry. He has a strong background in medical sciences and has worked on a broad range of indications and development approaches for chemical and biotechnological compounds.

Before joining MOLOGEN, he worked in various management positions with increasing responsibility in the international pharmaceutical, CRO and biotech industries.

From 2011 to 2017 he served as Chief Medical Officer and member of the Executive Board of NOXXON Pharma AG, a Berlin-based biotech 

company focused on novel cancer therapies. Here he was responsible for the planning and conduct of clinical development programs that brought three candidate molecules to clinical proof of concept.

From 2002 to 2010 he served as Chief Scientific Officer and Managing Director of FOCUS Clinical Drug Development, Neuss/Düsseldorf. In this role he was responsible for the design and execution of integrated programs progressing development compounds from the preclinical candidate stage to clinical proof of concept.

Prior to working for FOCUS, he served in various research and development roles at Roche and Boehringer Mannheim.

After receiving his MD degree from the University of Erlangen, Germany in 1984, Dr Baumann pursued 5 years of postgraduate training in the fields of oncology and immunology in Germany and the U.S.

He was born in 1958 and has the German citizenship. Dr Baumann is married.

Areas of responsibility at MOLOGEN:

  • Clinical Strategy
  • Preclinical & Clinical Development 
  • Regulatory Affairs
  • Research

External mandates:

  • Dr Baumann currently does not hold any other board memberships.

Fabeckstrasse 30
D - 14195 Berlin

T.  +49 (0)30 - 84 17 88 - 0
F.  +49 (0)30 - 84 17 88 - 50